Blood Cancers

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

2025 brought key advances in blood cancer treatment, research, and patient insights across multiple myeloma, lymphoma, leukemia and MDS.

All I can say is thank you Healthwell Foundation for giving our brother life, and for giving our whole family unit life. Because of you, we can keep on keeping on.

I attended this year’s Light the Night walk in remembrance of my sister, reflecting on her 11-year battle and enduring identity as a cancer survivor.

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Xervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

The FDA granted fast track status to UB-VV111 for patients with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia.

Dr. Christina Cho explains that a strong transplant program provides advanced treatments along with a supportive team for patients with blood cancers.

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United.

Your diagnosis of an early-stage blood cancer, such as a MPN or MDS, means that something has changed in the way your bone marrow produces blood cells.

Dr. Olalekan O. Oluwole, discusses treating patients from underserved communities with CAR T-cell therapy, as well as highlighted the therapy's evolution.

Doptelet and new oral sprinkle granules is approved for children one year and older with chronic immune thrombocytopenia, showing 28% durable platelet response in study.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.

In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared for her daughter while silently battling her own illness.

Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect quality of life over time.

Valarie Traynham discusses some of ways her life has changed since being diagnoses with cancer, and what parts of her identity have remained the same.

At age 19, I was a medical student with big dreams — until stage 4 blood cancer changed everything, leading to a journey of resilience and quiet hope.

Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.

CAR T-cell therapy may cure up to 40% of patients with lymphoma and is an option for those who can’t receive transplants, says Dr. André Goy.

Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.